April 12, 2021
Daiichi Sankyo said on April 9 that it has launched a PII clinical trial in Japan for its CSF-1R inhibitor pexidartinib in certain patients with symptomatic tenosynovial giant cell tumor (TGCT). The two-part study is enrolling 18 patients with TGCT...read more